

A single-cell map of antisense oligonucleotide activity in the brain

Meredith A Mortberg^{1*}, Juliana E Gentile^{1*}, Naeem Nadaf¹, Charles Vanderburg¹, Sean Simmons¹, Dan Dubinsky², Adam Slamin², Salome Maldonado², Caroline L Petersen², Nichole Jones², Holly B Kordasiewicz³, Hien T Zhao³, Sonia M Vallabh^{1,4,5,6†}, Eric Vallabh Minikel^{1,4,5,6†}

1. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
2. Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, 02141, USA
3. Ionis Pharmaceuticals, Carlsbad, CA, 92010, USA
4. McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
5. Department of Neurology, Harvard Medical School, Boston, MA, 02115, USA
6. Prion Alliance, Cambridge, MA, 02139, USA

*equal contribution

†correspondence to: svallabh@broadinstitute.org or eminikel@broadinstitute.org

ABSTRACT

Antisense oligonucleotides (ASOs) dosed into cerebrospinal fluid (CSF) distribute broadly throughout the brain and hold the promise of treating myriad brain diseases by modulating RNA. CNS tissue is not routinely biopsied in living individuals, leading to reliance on CSF biomarkers to inform on drug target engagement. Animal models can link CSF biomarkers to brain parenchyma, but our understanding of how individual cells contribute to bulk tissue signal is limited. Here we employed single nucleus transcriptomics on tissue from mice treated with RNase H1 ASOs against *Pmp* and *Malat1* and macaques treated with an ASO against *PRNP*. Activity was observed in every cell type, though sometimes with substantial differences in magnitude. Single cell RNA count distributions implied target suppression in every single sequenced cell, rather than intense knockdown in only some cells. Duration of action up to 12 weeks post-dose differed across cell types, being shorter in microglia than in neurons. Suppression in neurons was generally similar to, or more robust than, the bulk tissue. In macaques, PrP in CSF was lowered 40% in conjunction with *PRNP* knockdown across all cell types including neurons, arguing that a CSF biomarker readout is likely to reflect disease-relevant cells in a neuronal disorder.

INTRODUCTION

Antisense oligonucleotides (ASOs) can, in principle, modulate the expression of nearly any gene in the central nervous system (CNS), and hold the potential to treat myriad diseases¹. Typically short (~18-20 nucleotides) and chemically modified to improve pharmacokinetics and potency, ASOs are dosed directly into cerebrospinal fluid (CSF)². Upon binding cell surface proteins, ASOs become internalized into endosomes, from which they escape gradually over weeks³ and achieve sustained pharmacologic activity in the cytoplasm and nucleus⁴. An ASO designed to modulate pre-mRNA splicing — nusinersen for spinal muscular atrophy — received FDA approval in 2016⁵. 23 ASOs have entered clinical trials for CNS disorders^{1,6}, with several advancing to Phase III, along with others administered on an "N-of-1" basis^{7,8}. The majority of CNS ASOs in trials today are "gapmers" — ASOs with 2' sugar modifications in the wings (typically 5 base pairs on either side) and a "gap" in the middle with no modifications except for a phosphorothioate backbone² — designed to lower the expression of a target RNA by recruiting the enzyme RNase H1 to cleave it^{9–11}. For CNS diseases caused by a toxic gain of function, gapmer ASOs offer a rational approach to target the root cause of disease by lowering the toxic RNA or protein¹.

ASOs administered by bolus injection into CSF distribute broadly throughout the spinal cord and brain in rodents and monkeys^{12,13}, albeit with a drug concentration gradient from superficial to deep brain structures. Animal models of CNS diseases with various regional and cell type-specific pathologies have been phenotypically ameliorated or modulated with ASO treatment^{14–20}, and an ASO was shown active in at least four different cell types within mouse cortex at 2 weeks post-dose¹². These findings suggest that ASO activity is relatively broadly distributed within the CNS. Our understanding of gapmer ASO activity across distinct cell types in the CNS remains limited, as the vast majority of target engagement data ever generated for ASOs are based on analyses of bulk tissue. This knowledge gap is particularly salient when considering the interpretation of CSF-based target engagement biomarkers in ASO trials. Any cell type-specific differences in ASO uptake or activity, combined with drug concentration gradients, could generate variability in the degree of target engagement among relevant CNS cells. And yet, a pharmacodynamic biomarker value in a single sampling compartment, such as target knockdown in CSF, may underpin choices to advance or halt clinical programs, and in pre-symptomatic prion disease, may even support regulatory determinations²¹. A deeper understanding of the profile of ASO activity across cell types should help to inform such crucial decisions.

Here, we employed single nucleus RNA sequencing (snRNA-seq) to characterize the distribution of ASO activity across individual cells and across cell types in the mouse and cynomolgus macaque CNS.

MATERIALS AND METHODS

Mice. All mice were female C57BL/6N. Animals for 3 week post-dose harvest were dosed at the Broad Institute (IACUC protocol 0162-05-17) and were 16 weeks old at the time of dosing. Animals for 2 and 12 week post-dose harvest were dosed at Ionis Pharmaceuticals (IACUC protocol 2021-1176) and were 8-12 weeks old at dosing. Mice were dosed via intracerebroventricular injection as described²². ASOs were delivered as a single bolus injection of 500 µg (*Prrnp* ASOs) or 50 µg (*Malat1* ASO) formulated in a 10 µL volume of dPBS. Mice were perfused with HEPES-sucrose solution (110 mM NaCl, 10 mM HEPES, 25 mM glucose, 75 mM sucrose, 7.5 mM MgCl₂, 2.5 mM KCl, pH 7.4) and brains harvested as described^{23,24}.

Non-human primates. Cynomolgus macaque (*Macaca fascicularis*) studies were performed at Labcorp Early Development Services GmbH (Münster, Germany) under IACUC protocol 8422120. Studies complied with all of the following regulations: European Directive 2001/83/EC, German Drug Law Arzneimittelgesetz, International Conference on Harmonization (ICH) guidelines M3(R2) (Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals), ICH-S3A (Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies), ICH-S4 (Duration of Chronic Toxicity Testing in Animals), and ICH-S8 (Immunotoxicity Studies for Human Pharmaceuticals). Animals were 2-4 years old at injection, mixed sex (2M/2F per cohort), and were of Asian origin. Lumbar punctures were performed on days 1, 29, 57, and 85. The procedure was performed fasting under ketamine/medetomidine anesthesia with a pencil-point pediatric needle at a position between L2 and L6. First, ≥ 0.5 mL of CSF was collected, then, 20 mg ASO was delivered in a 1 mL volume of artificial CSF (aCSF) injected over 1 minute, followed by a flush of 0.25 mL aCSF. 15 minutes after the procedure, animals were awakened with atipamezole. CSF was ejected into Protein LoBind tubes and snap frozen in liquid nitrogen. The CSF samples analyzed here were collected at day 85, just prior to the fourth dose, while brain tissues were collected at day 92. Because the majority of CSF volume was used for regulated studies, the aliquots available for analysis in this study varied from 120-300 μ L and 0.03% CHAPS was added only after freeze/thaw; these pre-analytical factors likely contribute additional variability between samples²⁵.

Tissue dissection. For mouse brains, cryostat (Leica CM3050 S) dissection was performed as described²⁶: after storage in optimal cutting temperature (O.C.T.) compound (Tissue-Tek 4583) at -80°C , mouse brains were mounted by the frontal cortex onto cryostat chucks with O.C.T. leaving the entire posterior half of the brain exposed. A ~ 2.5 mg piece of tissue was then excised using a pre-chilled ophthalmic microscalpel (Feather P-715) and placed into a pre-chilled PCR tube. For mice, a piece of somatosensory cortex was used for snRNA-seq, while an adjacent piece of visual cortex was used for bulk qPCR; thalamus was cut along the fiber tract and the dorsal half was used for snRNA-seq while the ventral half was used for qPCR; cerebellum was cut through the ansiform lobule and a piece of simple/ansiform lobule was used for snRNA-seq while a piece of ansiform/paramedian lobule was used for qPCR. Cynomolgus brains were coronally sectioned at a thickness of 4 mm, and cylindrical tissue punches of 2 mm diameter were taken for RNA analysis and of 6 mm diameter for protein analysis. The 2 mm diameter by 4 mm length cylindrical tissue punch was then sectioned lengthwise into quarters on the cryostat and one quarter was used for single cell analysis. From the most rostral section containing frontal cortex, punches were taken from middle frontal gyrus across all histological cortical layers. From section 12, where both cerebellum and medulla are visible, punches were taken from the posterior lobe of the cerebellum across the granular, ganglionic and molecular layers.

Bulk tissue qPCR. Tissue pieces dissected on the cryostat were placed in RNAlater-ICE (Invitrogen AM7030) and allowed to thaw overnight at -20°C . Once samples were thawed, tissue was homogenized in 1 mL QIAzol lysis reagent, using 3 x 40 second pulses on a Bertin MiniLys homogenizer in 7 mL tubes pre-loaded with zirconium oxide beads (Precellys CK14, Bertin KT039611307.7 / P000940-LYSK0-A). RNA was isolated from homogenate using RNeasy Lipid Tissue Mini Kit (Qiagen 74804) per the manufacturer protocol. RNA was eluted with 40 μ L RNase-free water. RT-PCR samples were prepared using Taqman 1-Step RT-PCR master mix (Invitrogen) and Taqman gene expression assays (Invitrogen) for mouse *Prnp* (Mm00448389_m1; spanning exons 1-2) and mouse *Tbp* (Mm00446971_m1) and for cynomolgus *TBP* (Mf04357804_m1). The following gene-specific primer-probe sets were

custom ordered from IDT: *Malat1* (mouse), Forward: AGGCGGGCAGCTAAGGA, Reverse: CCCCAGTGTCCATCCTCCA, Probe: TTCCTCTGCCGGTCCCTCGAAAG; *PRNP* (cynomolgus; spanning intron 1 - exon 2), Forward: CCTCTCCTCACGACCGA, Reverse: CCCCAGTGTCCATCCTCCA, Probe: CCACAAAGAGAACCAGCATCCAGCA. Samples were run on a QuantStudio 7 Flex system (Applied Biosystems) using manufacturer's recommended cycling conditions. Each biological sample was run in duplicate and the level of all targets were determined by $\Delta\Delta C_t$ whereby results were first normalized to the housekeeping gene *Tbp* and then to PBS- or aCSF-treated animals.

Single cell sequencing. After cryostat dissection, samples were batched in groups of eight, chosen to include treated and control animals in every run. Single nucleus suspensions were prepared as described^{27,28}. Briefly: tissue samples were triturated, by pipetting, in an extraction buffer containing Kollidon VA64, Triton X-100, bovine serum albumin, and RNase inhibitor, then passed through a 26-gauge needle, washed and pelleted, then passed through a cell strainer. Nuclei positive for DAPI signal were isolated by fluorescence-activated cell sorting with a Sony SH800 or MA900 calibrated with a 70 μm chip, with a 405 nm excitation laser and light collected with a 425 - 475 nm filter. Sorted nuclei were counted using a Fuchs-Rosenthal C-Chip hemocytometer and a hand tally counter. A volume chosen to target 17,000 nuclei was submitted to the Broad Institute's Genomics Platform, where 10X library construction (3' V3.1 NextGEM with Dual Indexing) was performed according to manufacturer instructions²⁹. Libraries were sequenced on an Illumina Novaseq 6000 S2 for 100 cycles.

Data processing and analysis. Raw binary base call (BCL) files were synced to Google Cloud and analyzed on Terra.bio. Cumulus³⁰ Cell Ranger³¹ 6.0.1 (cellranger_workflow v28) was employed, with flags `--include_introns` and `--secondary set to true`, to process BCL files into unique molecular identifier (UMI) count matrices for each individual sample. Mouse samples were aligned to Cell Ranger reference package mm10-2020-A and cynomolgus samples were aligned to a custom Cell Ranger reference made from Ensembl *Macaca fascicularis* 6.0 (release 108). Matrices were then aggregated using Cell Ranger 7.0.1 (aggr with the `--normalize` flag set to none) to yield one UMI count matrix per species and brain region. Statistical analyses and data visualization were conducted using custom scripts in R 4.2.0.

Cell type assignment. Aggregated count matrices were examined using Loupe Browser. Viewing cells in 2-dimensional uniform manifold approximation and projection (UMAP)³² space, we looked for cell type markers established or validated in several prior single-cell studies^{26,33-39}. Clusters corresponding to empty droplets, doublets, debris, or mitochondria were flagged and removed based on low UMI or unique gene count, low percentage intronic reads, lack of obvious differentially expressed genes, high expression of mitochondrial genes, or location between two other clusters and expression of markers of each. Assignments were then validated by generating dot plots in Seurat V4⁴⁰ in R. For cortical excitatory and inhibitory neurons in 3 week post-dose animals, a list of barcodes was exported from R and reclustered in Loupe Browser.

Statistics. For each combination of brain region, timepoint, and treatment condition, snRNA-seq data were grouped by animal and cell type and the sum of target UMIs and total UMIs was calculated. A negative binomial model was fit to the resulting data, with target RNA UMIs as the dependent variable; cell type and a cell type-treatment interaction term as the dependent variables, and total UMIs as the offset. This utilized the MASS package in R, with the call: `glm.nb(target_umi ~ celltype + celltype:treatment + offset(log(total_umi)))`. This returns coefficients in natural logarithm space. For the ASO-treated conditions, the coefficient for each cell type-treatment interaction term coefficient was then exponentiated to yield the mean

estimate of the residual target RNA in that cell type. The 95% confidence interval was defined as that mean estimate ± 1.96 of the standard errors returned by the model. Each individual animal's point estimate of residual target RNA in each cell type was obtained by adding the residual from the model to the cell type-treatment coefficient, and then exponentiating. To account for the different abundance of different cell types, which impacts the size of our confidence intervals on target knockdown, we used weighted Pearson's correlations (`wtd.cor` from the `weights` package in R) to test candidate variables and weighted standard deviations (square root of `wtd.var` from the `Hmisc` package in R) to evaluate the variability in target engagement between cell types within different brain regions. Throughout, all error bars and shaded areas in figures represent 95% confidence intervals. P values less than 0.05 were considered nominally significant.

Data availability. A public git repository will be made available at <https://github.com/ericminikel/scaso> containing all source code and a minimum analytical dataset (~200 MB) sufficient to reproduce most figures and statistics in this manuscript. The full dataset (~8 TB) will be deposited at singlecell.broadinstitute.org and made available through a public Terra repository.

RESULTS

Generation and cell type classification of single nucleus transcriptomes.

We selected 4 previously characterized ASOs (Table 1) including 2 *Prnp* ASOs for which we have evaluated survival benefit in prion-infected mice^{22,41}, 1 *Malat1* ASO for which an extensive regional pharmacokinetic and pharmacodynamic atlas has been published¹², and 1 human *PRNP* ASO sequence-matched in cynomolgus macaques⁴². We analyzed a total of 78 single nucleus transcriptomes from tissues of mice and macaques treated with these ASOs or with vehicle (Table 2). For mouse *Prnp* tool compounds, we used a dose of 500 μ g evaluated in survival studies^{22,41}, whereas for the more potent *Malat1* ASO, we used a 50 μ g dose¹². Each sample yielded an average of 532 million reads mapping to 7,667 cells and yielding 7,650 unique molecular identifiers (UMIs) per cell, corresponding to a median of 3,108 detected genes per cell (Table S1).

ASO	sequence and chemistry	target	ref
ASO 1	mCToAoTTTAATGTmCAoGoTmCT	mouse <i>Prnp</i> 3'UTR	22,41
ASO 6	mCToTomCoTATTTAATGTmCAoGoTmCT	mouse <i>Prnp</i> 3' UTR	22
<i>Malat1</i> ASO	GCocAoGoGCTGGTTATGAocCoTCA	mouse/NHP <i>Malat1</i>	12
ASO N	GToCoAoToAoATTTTCTTAGCoTAC	human/NHP <i>PRNP</i> intron	42

Table 1. Compounds used in this study. Color code for ASO chemical modifications: black = unmodified deoxyribose (2'H; DNA). orange = 2' methoxyethyl (MOE). blue = 2'-4' constrained ethyl (cET). Unmarked backbone linkages = phosphorothioate (PS); linkages marked with o = normal phosphodiester (PO). mC = 5-methylcytosine.

species	treatment	dose	brain region	weeks post-dose	N animals
mouse	PBS	—	cortex	2	4
mouse	ASO 1	500 µg 1x	cortex	2	4
mouse	ASO 6	500 µg 1x	cortex	2	4
mouse	ASO 6	500 µg 1x	cortex	3	4
mouse	PBS	—	cortex	3	7
mouse	ASO 6	500 µg 1x	thalamus	3	3
mouse	PBS	—	thalamus	3	4
mouse	PBS	—	cerebellum	3	4
mouse	ASO 6	500 µg 1x	cerebellum	3	4
mouse	PBS	—	cortex	12	4
mouse	ASO 1	500 µg 1x	cortex	12	4
mouse	ASO 6	500 µg 1x	cortex	12	4
mouse	PBS	—	cerebellum	12	4
mouse	ASO 6	500 µg 1x	cerebellum	12	4
mouse	Malat1 ASO	50 µg 1x	cerebellum	12	4
cynomolgus	aCSF	—	cerebellum	13	4
cynomolgus	ASO N	20 mg 4x	cerebellum	13	4
cynomolgus	aCSF	—	cortex	13	4
cynomolgus	ASO N	20 mg 4x	cortex	13	4

Table 2. Summary of samples analyzed by single-cell sequencing. Identities of active compounds are shown in Table 1; aCSF = artificial CSF; PBS = phosphate-buffered saline. Note that weeks post-dose is after a single dose for mice, whereas cynomolgus macaques received 4 doses at 4 week intervals and were sacrificed after 13 weeks, 1 week after the final dose.

Single nucleus transcriptomes were aggregated by species and brain region to yield five count matrices. These were projected into a two-dimensional space using uniform manifold approximation and projection (UMAP; Figure 1) revealing distinct clusters corresponding to specific cell types. Cell types assigned using established markers were validated using dot plots to visualize the specificity of gene expression (Figure 1).

Distribution of ASO activity at the single cell level.

The long non-coding RNA *Malat1* is a valuable model target for single cell assessment of ASO activity because it is highly expressed, accounting for 11.4% of all UMIs in our mouse transcriptomes, and because a potent and well-characterized tool ASO against *Malat1* is available¹². Considering this compound's median effective dose (ED₅₀) of ~50 µg in cerebellum¹² and the prior evidence for some difference in activity between cerebellar cell types^{12,19}, we examined *Malat1* knockdown in cerebellum at 12 weeks after a single 50 µg ICV dose of *Malat1* ASO. Aggregation of single nucleus sequencing data across all mouse cerebellar nuclei indicated 45.4% residual *Malat1*, close to the 52.4% residual detected in an adjacent piece of cerebellar tissue analyzed by bulk qPCR (Figure 2A; Table S2-S3). When *Malat1* UMIs per cell were visualized as a histogram (Figure 2B), the median cell possessed 360 *Malat1* UMIs in PBS-treated animals. ASO treatment yielded a bimodal histogram, with a main peak at 166 UMIs but a second peak at ~35 UMIs (black arrow, Figure 2B) indicating deeper knockdown in a subpopulation of cells. Across 14 different cell types (Figure 2C), residual *Malat1* ranged from 7% to 76%, while each individual histogram appeared unimodal. This suggested that the bimodality in the histogram for bulk tissue (Figure 2B) is due to differences in knockdown in different cell types. Scatterplots of *Malat1* UMIs vs. total UMIs indicated that the width of the distributions in these histograms is largely due to differences in total UMIs per cell. All of these observations were consistent with broad knockdown in every detected cell. Fitting residual *Malat1* in each cell type in each sample with a negative binomial model (see Materials and Methods) confirmed substantial differences in knockdown between cell types (Figure 2D; Table S4-S6).




Figure 2. Single-cell distribution of ASO activity in mouse cerebellum at 12 weeks post-dose. *N* = 4 mice per group received 50 μ g *Malat1* ASO, 500 μ g ASO 6, or PBS ICV and cerebella were harvested 12 weeks later. **A)** *Malat1* knockdown after *Malat1* ASO treatment, assessed by bulk qPCR (x axis) versus aggregation of single cell sequencing regardless of cell type (y axis), for individual animals (points) and groups (crosshairs indicate means and 95% confidence intervals). **B)** Histogram of the number of *Malat1* UMIs per single cell across all samples. Arrow indicates a second peak observed only for treated animals. **C)** Breakdown across 14 cell types. Top panels are histograms of single cells as in B, but broken down by cell

type. Bottom panels are scatterplots showing total UMIs per single cell versus *Malat1* UMIs per cell and best fits by linear regression (Table S8). Percentages indicate residual *Malat1*. Note the "key" panels at the far right of the middle row. **D**) Negative binomial (NB) modeling of single cell data as point estimates of knockdown for each animal and each cell type (points) and means and 95% confidence intervals (bars) for each treatment group and cell type. **E**) Correlation across cell types of *Prnp* knockdown by ASO 6 and *Malat1* knockdown by *Malat1* ASO. Each point is a cell type, colors are from Figure 1A, and point sizes are logarithmically scaled with number of cells sequenced. **F**) Histogram of *Prnp* UMIs per single cell in astrocytes for PBS (gray) and ASO 6-treated animals (cyan). Shaded gray bars indicate the distribution predicted by a NB model fit to the PBS data. Shaded red bars indicate the distribution if the observed 56% residual *Prnp* RNA in astrocytes corresponded to 56% of cells following the original NB distribution and 44% being set to zero. Shaded cyan bars indicate the distribution if the observed 56% residual corresponded to the NB parameter μ being reduced by 44%.

snRNA-seq inherently yields low sequencing coverage in any one nucleus: our count matrices, measuring ~30,000 genes long by ~60,000 - 270,000 nuclei wide, were 87.2 - 93.2% populated by zeroes (Table S7). In other words, most genes are not detected in most nuclei, even where they are expressed. Thus, unlike *Malat1*, whose expression in single nuclei was normally distributed, most potential ASO targets will have UMI counts that are Poisson or negative binomial distributed in single nuclei data. For instance, *Prnp* averaged just 0.85 UMIs/cell in the cerebella of PBS-treated animals. Nevertheless, when the data from 12 weeks after a single 500 μg dose of ASO 6, were fit to the same negative binomial model as *Malat1*, ASO 6 displayed a highly similar pattern of activity across cerebellar cell types ($\rho = 0.96$, $P < 3.9\text{e-}8$, weighted Pearson's correlation; Figure 2E; Table S6).

Despite the lower basal expression of *Prnp*, we posited that examination of the histograms of UMIs/cell for *Prnp* could reveal information about the distribution of drug activity across single cells. As an example, we considered astrocytes, which had 56% residual *Prnp*, comparing histograms of actual *Prnp* UMIs/cell in PBS and ASO 6-treated animals versus three models. A negative binomial model fit to the PBS-treated animals mirrored these animals' actual distribution almost perfectly. Lowering *Prnp* to 56% residual by setting 44% of astrocytes' *Prnp* counts to zero would have yielded a histogram with far more zeroes, and fewer ones, than the observed distribution in ASO 6-treated animals. In contrast, lowering *Prnp* to 56% residual by lowering the negative binomial parameter μ by 44%, corresponding to equal knockdown in all cells, yielded a distribution that closely mirrored the observed distribution in ASO-treated animals (Figure 2F; Table S9). Thus, for *Prnp* as for *Malat1*, bulk tissue knockdown appears to arise from broad knockdown in all cells, albeit with a stereotypical pattern of differences across distinct cell types.

ASO activity across regions and cell types in the mouse brain.

We assessed the profile of ASO target engagement across cell types in 3 brain regions in mice at 3 weeks post-dose with *Prnp* ASO 6 (Figure 3). Because this tool compound is less potent than the *Malat1* ASO, we used a 500 μg dose, which modifies prion disease in mice^{22,41} and lowers whole hemisphere PrP to an estimated 56% residual after 4 weeks⁴³. Whereas *Malat1* localizes to the nucleus⁴⁴, *Prnp* is a protein-coding gene whose mRNA reaches the cytosol, and ASO 6 targets the *Prnp* 3'UTR, so cytosolic activity is possible. Nonetheless, we found that the value of residual *Prnp* obtained by snRNA-seq, which will detect nuclear ASO activity only, agreed closely with the value obtained by bulk tissue qPCR, which used exon junction-spanning primers and therefore will only detect mature mRNA (Figure 3A-C).




Figure 3. Atlas of ASO activity across cell types in mouse brain at 3 weeks post-dose.

Mice 3 weeks after a single 500 μ g dose of ASO 6. **A-C**) Concordance of bulk qPCR (x axis) and single cell (y axis) measurement of total *Prnp* knockdown in cortex (A), thalamus (B), and cerebellum (C). Points are individual animals, crosshairs are 95% confidence intervals on both dimensions. **D**) Residual *Prnp* expression across cell types in three brain regions. Error bars are 95% confidence intervals of the mean. **E**) Cortical excitatory neurons from panel A were reclustered into 15 clusters ranked by expression of four excitatory layer markers. Residual *Prnp* (top) is shown as individual animals (points), means (lines), and 95% confidence intervals of the mean (shaded areas). Each marker's expression (bottom) is normalized to the cluster with the highest expression; points are normalized values and curves are loess fits. **F**) Cortical inhibitory neurons from panel A, reclustered and plotted as in panel B. **G-I**) Scatterplots of residual *Prnp*

expression (*y* axis) versus candidate covariates (*x* axes). Each point represents a region and cell type combination from panel D (cortical fibroblasts, the only cell type with nominally >100% residual expression, are not visible). Colors correspond to cell type colors in Figure 1, and dot sizes scale logarithmically with the number of cells sequenced. Candidate covariates examined are *Rnaseh1* expression in UMIs per million (UPM; G), total UMIs per cell (H), and basal *Prnp* expression (UPM; I).

Breakdown of single cell data by cell type showed broad target engagement across cell types including diverse types of neurons and glia (Figure 3D). As with the *Malat1* ASO (Figure 2), cell type differences were relatively pronounced in the cerebellar neurons, where knockdown was deeper in Purkinje cells and MLI than in granule cells. Across regions in ASO-treated animals, endothelial stalk cells, pericytes, and fibroblasts generally had both the highest residual *Prnp* and the lowest count of cells sequenced, giving rise to wide confidence intervals that overlapped the PBS-treated animals. Nonetheless, point estimates for these cells generally suggested some target engagement, with the possible exception of cortical fibroblasts. To further examine the profile of knockdown among neuronal subtypes, we reclustered cortical excitatory (Figure 3E; Table S10) and inhibitory (Figure 3F; Table S11) neurons and ordered them by relative expression of excitatory layer or inhibitory subtype markers. Target engagement appeared similar across all layers of excitatory neurons (Figure 3E). Knockdown appeared possibly deeper in *Pvalb*-expressing than in *Vip*-expressing inhibitory neurons, but again, target engagement was observed across all subtypes (Figure 3F).

Across all regions, we asked whether the differences in residual *Prnp* across cell types could be explained by any obvious candidate variables. *Rnaseh1* expression varied little among cell types and did not predict knockdown ($P = 0.61$, weighted Pearson's correlation; Figure 3G). Total UMIs per cell, a potential proxy for cell size²⁶, and basal *Prnp* expression, were likewise uncorrelated ($P = 0.64$ and $P=0.08$, weighted Pearson's correlation; Figure 3H-I; see Discussion).

Potency and duration of action across ASO chemistries.

Gapmer ASOs currently in clinical trials are 2'MOE gapmers similar to ASO 6, but improved chemical modifications of ASOs are a highly active area of research^{45,46}, prompting us to investigate the cell type profile of an ASO incorporating 2'-4' constrained ethyl (cEt) modifications⁴⁷. *Prnp* ASO 1 (Table 1), a mixed 2'MOE/cEt oligonucleotide, targets the same site as ASO 6 and is effective in prion-infected mice^{22,41}. We evaluated the activity of ASO 1 and ASO 6 in mouse cortex at both 2 and 12 weeks after a single 500 μ g bolus dose (Figure 4). As before, despite the 3'UTR target of these ASOs, single cell and bulk qPCR measurements of overall knockdown were in reasonable agreement (Figure 4A). ASO 1 had a shorter duration of action than ASO 6, with residual target rising from 47% to 91% of saline controls (by bulk qPCR) residual, a 44% recovery, versus 31% to 65%, a 34% recovery, for ASO 6 (Figure 4A; Table S3). Each compound provided substantial knockdown at 2 weeks across all cell types detected, and each exhibited marked differences across cell types in the rate of recovery (Figure 4B; Table S12). For example, for both ASOs, microglia exhibited the most complete recovery of any cell type (+51% for ASO 6 and +70% for ASO 1), while excitatory neurons were comparatively steady (+29% for both; Figure 4B).




Figure 4. Duration of activity across different ASO chemistries in mouse cortex from 2 to 12 weeks post-dose. Groups of $N = 4$ mice received PBS, 500 μg ASO 1, or 500 μg ASO 6 and cortex was evaluated after 2 or 12 weeks. **A)** Overall residual Prnp assessed by bulk qPCR (x axis) versus aggregate single cell data without regard to cell type (y axis). Points represent individual animals and crosshairs represent means and 95% confidence intervals on both axes. 2 week data (lower left) and 12 week data (upper right) are connected by arrows indicating washout for both ASO 1 (dark blue) and ASO 6 (cyan). **B)** Washout from 2 weeks (left) to 12 weeks (right) for each cell type in mouse cortex for ASO 1 and ASO 6. Lines represent means and shaded areas represent 95% confidence intervals. **C-E)** Scatterplots of candidate variables (x axis) basal Prnp expression (UMIs per million, UPM; C), Rnaseh1 expression (UPM; D), and 2 week residual Prnp (E) versus percentage points of recovery (washout at 12 vs. 2 weeks, y axis) for each cell type (cell types are points, sized logarithmically by number of cells) for both ASO 1 (dark blue) and ASO 6 (cyan).

Across both compounds, neither basal Prnp expression (RPM in PBS-treated animals) nor Rnaseh1 expression showed any correlation with washout between 2 and 12 weeks ($P = 0.78$ and $P = 0.12$, weighted Pearson's correlation; Figure 4C-D). The depth of target suppression at 2 weeks post-dose, however, showed an inverse correlation with recovery by 12 weeks which was significant for ASO 1 ($\rho = -0.84$, $P = 0.0043$, weighted Pearson's correlation) and directionally consistent for ASO 6 ($\rho = -0.41$, $P = 0.27$, weighted Pearson's correlation; Figure 4E; see Discussion).

Cell type profile and biomarker impact in non-human primates.

We examined tissue from cynomolgus macaques that received ASO N. In addition to permitting us to examine ASO activity in a larger brain, the macaques also differed from our mice in being dosed intrathecally (IT) rather than ICV, and receiving 4 repeat doses at 4-week intervals. In cortex, bulk residual PRNP measured by snRNA-seq again mirrored that by qPCR (Figure 5A), although in cerebellum, knockdown measured by snRNA-seq appeared slightly deeper (Figure 5B). Residual PrP protein level quantified by ELISA⁴³ in ASO N-treated animals was 41% in cortex, 82% in cerebellum and 60% in CSF (Figure 5C; Table S13-S14). Target engagement was broadly observed across all detected cell types in both cortex and cerebellum (Figure 5D; Table S6). In cortex, knockdown was deepest in neurons and weakest in endothelial stalk and pericytes/fibroblasts. In cerebellum, knockdown was deepest in Purkinje cells and molecular layer interneurons (MLIs) and weakest in pericytes/fibroblasts. Because these tissues were obtained just 1 week after the animals' final dose of ASO, we compared the cell type profile of target engagement in macaques to that observed in mice 2 weeks after a single dose of ASO 6 (Figure 5E-F). The two datasets shared robust knockdown in the aforementioned neuronal populations and relatively limited knockdown in pericytes/fibroblasts. Correlation of residual

target percentages across cell types was positive but non-significant for cortex ($\rho = 0.40$, $P = 0.33$, weighted Pearson's) and positive and significant for cerebellum ($\rho = 0.80$, $P = 0.0019$, weighted Pearson's).




Figure 5. Cell type activity distribution and biomarker response in non-human primates. $N = 4$ cynomolgus macaques per group received 20 mg ASO N at weeks 0, 4, 8, and 12, and cortex and cerebellum were evaluated at week 13. **A-B)** PRNP knockdown assessed by bulk qPCR (x axis) versus aggregation of single cell sequencing regardless of cell type (y axis), for individual animals (points) and groups (crosshairs indicate means and 95% confidence intervals) in cortex (A) and cerebellum (B). **C)** PrP protein measured by in-house ELISA⁴³ in brain parenchyma (cortex, cerebellum) and in cerebrospinal fluid (CSF). **D)** Residual PRNP by cell type in cortex and cerebellum. **E-F)** Scatterplot of cynomolgus 13-week residual PRNP by cell type (x axis) versus mouse residual Prnp at 2 weeks after a single dose of ASO 6 (data from Figure 3A) in cortex (E) and cerebellum (F). The data point for pericyte/fibroblast reflects the weighted average of residual Prnp in these two cell populations in mouse. Each point is a cell type, sized logarithmically by total number of cells (cynomolgus + mouse datasets) and colored as in Figure 1.

Comparison of cell type specificity across paradigms.

We next asked more broadly how well the profile of target engagement across cell types was shared among all of the conditions examined herein. To normalize between ASOs and

timepoints with different levels of target engagement, we defined a difference from overall residual as a cell type's residual target RNA, expressed as a percentage of control animals, minus the overall residual target RNA across all cell types (Table S15). Thus, positive differences indicate that a cell type has weaker knockdown than the bulk tissue, while negative differences mean deeper knockdown. In cortex, the most abundant cell types, chiefly neurons, clustered near 0% (excitatory neurons, mean +1%, inhibitory neurons, mean +2%), reflecting the bulk tissue closely, while outliers were relatively rarer cell types for which our confidence intervals on the amount of residual target are wider (Figure 6A). In cerebellum, by contrast, large differences were observed between granule cells (mean +7%) and the next two most abundant cell types, MLIs (-30%) and Bergmann glia (-10%). Overall, variability across cell types was lower in cortex and thalamus (mean weighted standard deviation 7% for both) than in cerebellum (mean weighted standard deviation 12%; Figure 6A). Accordingly, when we tested the correlation across cell types between every pair of datasets within each tissue, we observed mostly positive but non-significant correlations for cortex (Figure 6B; Table S15), whereas all correlations were strongly positive and significant in cerebellum (Figure 6C; Table S16). Because prion disease affects all neurons, we examined the estimated differences from overall residual for every neuronal subtype in every dataset (Figure 6D; Table S17). Neurons were generally either close to the bulk tissue residual (worst case, +12% difference for granule cells in *Malat1* ASO-treated mouse cerebellum at 12 weeks) or exhibited much deeper target engagement (-38% for MLIs in *Malat1* ASO-treated mouse cerebellum at 12 weeks). We did not observe any conditions in which any population of neurons exhibited dramatically weaker knockdown than the bulk tissue.




Figure 6. Comparison of cell type target engagement profiles across all conditions examined. **A)** Top: differences from overall residual (each cell type's residual target minus the overall residual target quantified from single-nucleus data; y axis) for every combination of tissue, ASO, timepoint, and species (shared x axis). Each point is a cell type, sized logarithmically by number of cells and colored as in Figure 1. Bottom: weighted standard deviations (weighted by number of cells) in percentage points of residual target (y axis) for each condition (shared x axis). **B-C)** Correlograms (weighted Pearson's correlations) between every pair of datasets for cortex (B) and cerebellum (C). Colors represent the value of the correlation coefficient ρ and the outline represents the nominal P value, see legend at far right. **D)** Differences from overall residual for all neuronal subtypes in all conditions. Error bars are 95% confidence intervals from the negative binomial models for the subtype-specific residuals.

DISCUSSION

Theoretically, 50% knockdown in bulk tissue could result, in the most extreme cases, from either 100% knockdown in half of cells or 50% knockdown in all cells. A longstanding question is where the activity of CNS ASOs falls on this spectrum. By examining the distribution of target RNA counts per cell in single nucleus sequencing data, we provide evidence of ASO activity in every single cell in a bulk tissue, albeit with differences in degree between cell types. This should be expected based on the number of drug molecules contained in a dose of ASO. For a mouse with $\sim 10^8$ brain cells^{48,49}, a 50 μg dose of a ~ 7 kDa ASO, or $\sim 4 \times 10^{15}$ ASO molecules, is $>10^7$ molecules per brain cell. Only a small minority of ASO molecules are believed to undergo productive uptake³, but even if this figure is 1%, then 10^5 productive ASO molecules per brain cell is a sufficient number that it is unlikely that any cells would avoid ASO activity simply by chance. In cynomolgus macaques, ASO concentration in some deep brain regions remains below the lower limit of quantification after intrathecal dosing¹². Thus, in a large brain, there may be cells lacking any appreciable ASO activity due to limited drug distribution. The compounds, dosing regimes, and tissues that we chose to analyze were chosen to select scenarios with robust target engagement at the bulk tissue level, and our data argue that under this precondition, ASO activity is very broadly distributed across individual cells. This property of ASOs could prove markedly different from some gene therapy approaches to CNS diseases. In mice, engineered viral vectors for gene delivery may transduce $\sim 50\%$ of CNS neurons⁵⁰, and DNA-targeted therapeutics, with only 2 targets per cell, could provide nearly complete target suppression in those cells that are transduced. If so, modalities exhibiting similar levels of bulk target engagement could reflect rather distinct distributions at the single-cell level. These contrasting profiles might in turn present opposing challenges and opportunities for different targets.

ASOs are internalized by binding cell surface proteins⁵¹ and travel through different cellular uptake pathways, only a subset of which are productive, eventually escaping from endosomes to bind their targets and (for gapmer ASOs) engage RNase H1 in the cytosol and nucleus³. This process presents many potential opportunities for distinct cell types to exhibit differential ASO activity, including: differences in total uptake, in the proportion of productive uptake, in the kinetics of endosomal escape, and in the rate of RNase H1 cleavage. Histological analysis of ASO-treated brain tissue has suggested that the difference in ASO activity between granule and Purkinje cells that we observe here is likely associated with a difference in total ASO uptake^{12,19}. Whether total uptake explains all of the cell type differences we observe remains to be seen. Across cell types in the mouse cortex, deeper initial target engagement at 2 weeks appeared to correlate with more washout by 12 weeks. This correlation is expected to some degree, because target expression after washout should never recover to $>100\%$ of the untreated condition, but may also suggest that deeper initial knockdown in some cell types does not necessarily indicate a longer-lasting endosomal repository of compound.

Our dataset is ill-suited to ask genome-wide questions such as which specific cell surface proteins are most important for uptake, because any two cell types differ in the expression of many markers, not just one, and in addition, the thousands of possible answers present a large multiple testing burden which cannot be overcome by analyzing the small number of distinct cell types detected here. Cell size might be inversely related to the surface area to volume ratio, and thus to the amount of opportunity for cell surface protein binding, but UMIs/cell, a proxy for cell size²⁶, was not correlated with ASO activity in our dataset. RNase H1 expression varied little across cell types and neither RNase H1 nor target expression correlated with initial target engagement or washout. In fact, this should be expected based on the number of drug

molecules per cell. PrP RNA expression is on the order of hundreds of transcripts per million⁵², so a cell with 10^5 mRNA molecules might have just tens of PrP mRNA molecules, not nearly enough to saturate 10^5 productively uptaken ASO molecules.

Our study has many limitations. The expense of single-cell sequencing limited us to small cohort sizes (usually $N = 4$). For some rarer cell types, just a handful of cells per sample were observed. Many steps including nuclei dissociation, flow cytometry, and library construction, can all yield variability in number of cells and number of sequencing reads per sample. All of these factors combine to make the confidence intervals on our estimates of knockdown in many cell types rather large. Certain key observations replicate across our datasets — particularly the broadness of target engagement across cell types, with weaker knockdown in granule cells and deeper knockdown in Purkinje and interlayer neurons, and the generally weaker knockdown in cells of the vasculature. However, we studied only 3 brain regions, 4 ASOs, 2 targets, and 2 animal species, so it remains to be determined just how broadly these findings may generalize. We lack any method of quantifying drug concentration in the same cells that are sequenced, so are unable to answer questions about the pharmacokinetic/pharmacodynamic relationship at the single-cell level. Because we relied on purification of nuclei from frozen tissue, we were only able to measure target engagement in the nucleus. It is reassuring that the percentage knockdown measured by snRNA-seq was generally close to the value obtained by qPCR. However, it is not possible to perform snRNA-seq and qPCR on the exact same piece of tissue, so we instead compared adjacent pieces of tissue. On the occasions where these values diverge, we are uncertain whether it represents discordance between cytosolic and nuclear outcomes, or simply regional gradients in target engagement.

Pharmacologic interventions are seldom trialed in pre-symptomatic individuals at risk for neurodegenerative disease⁵³. Observing clinical endpoints in such individuals may require lengthy follow-up⁵⁴ or may be outright numerically infeasible⁵⁵. This has led to the suggestion that in prion disease, where the central role of PrP in disease is incontrovertible⁵⁶, the lowering of CSF PrP — a target engagement biomarker only — could serve as a primary endpoint in trials of at-risk individuals²¹. This prospect demands that especially strong data from animal studies will be needed to certify the links between CSF PrP, target engagement in the disease-relevant cells, and modification of disease⁵⁷. In prion disease, the critical cells to engage are neurons. Although astrocytes may contribute to disease by propagating prions^{58–60}, only neurons degenerate in prion disease, and neurotoxicity is cell autonomous: neurons that do not express PrP are protected even if they are in direct contact with misfolded prions produced by neighboring cells^{60–62}. In contrast, neuroinflammatory responses from astrocytes and microglia^{63–66} appear to be strictly non-autonomous, requiring neuronal prion infection⁶⁰. That PrP-lowering ASOs extend survival in prion-infected mice^{22,41,67} implies that they must lower PrP in neurons; nevertheless, we felt it prudent to further examine this link to determine whether there might ever exist circumstances in which a bulk tissue readout would indicate PrP lowering despite little or no target engagement in neurons. It is reassuring, then, that across a range of experimental parameters — dosing regimens, times post-dose, ASO chemistries and gapmer configurations, targets, species, and brain regions — we never identified a circumstance in which bulk tissue would misinform about PrP RNA having been lowered in neurons. Of course, given the somewhat differing activity of ASOs in distinct CNS cell types and the potential for drug concentration gradients across the brain, no single compartment readout, such as CSF PrP, can accurately report on every disease-relevant cell in this whole brain disease. Still, our findings provide one pillar of support for the expectation that lowered CSF PrP in an ASO trial is reasonably likely to predict clinical benefit in individuals at risk for prion disease.

DISCLOSURES

SMV has received speaking fees from Ultragenyx, Illumina, and Biogen, consulting fees from Invitae, and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River. EVM has received consulting fees from Deerfield and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River. HTZ and HBK are employees and shareholders of Ionis Pharmaceuticals.

ACKNOWLEDGMENTS

This study was funded primarily by the Ono Pharma Foundation (Oligonucleotide Medicine Award 2019) and by Ionis Pharmaceuticals. The authors also acknowledge support from the National Institutes of Health (R21 TR003040 and R01 NS125255). The authors are grateful to Bo Li, Brian Granger, Brittany Ford, Briana Buscemi, and the Broad Institute Flow Cytometry Facility for technical assistance, to Joe Schroeder and Tom Zanardi for monitoring the NHP study, and to C. Frank Bennett for critical feedback on the manuscript.

REFERENCES

1. Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense Drugs Make Sense for Neurological Diseases. *Annu Rev Pharmacol Toxicol*. 2021 Jan 6;61:831–852. PMID: PMC8682074
2. Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. *Nat Rev Drug Discov*. 2021 Jun;20(6):427–453. PMID: 33762737
3. Crooke ST, Wang S, Vickers TA, Shen W, Liang XH. Cellular uptake and trafficking of antisense oligonucleotides. *Nat Biotechnol*. 2017 Mar;35(3):230–237. PMID: 28244996
4. Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. *Mol Ther*. 2017 06;25(9):2075–2092. PMID: PMC5589097
5. Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. *Nat Neurosci*. 2017 Apr;20(4):497–499. PMID: 28192393
6. ClinicalTrials.gov.
7. Synofzik M, van Roon-Mom WMC, Marckmann G, van Duyvenvoorde HA, Graessner H, Schüle R, Aartsma-Rus A. Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. *Nucleic Acid Ther*. 2022 Apr;32(2):83–94. PMID: PMC9058873
8. Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, Pendergast MK, Goldkind SF, Lee EA, Kuniholm A, Soucy A, Vaze J, Belur NR, Fredriksen K, Stojkowska I, Tsytsykova A, Armant M, DiDonato RL, Choi J, Cornelissen L, Pereira LM, Augustine EF, Genetti CA, Dies K, Barton B, Williams L, Goodlett BD, Riley BL, Pasternak A, Berry ER, Pflöck KA, Chu S, Reed C, Tyndall K, Agrawal PB, Beggs AH, Grant PE, Urion DK, Snyder RO, Waisbren SE, Poduri A, Park PJ, Patterson A, Biffi A, Mazzulli JR, Bodamer O, Berde CB, Yu TW. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019 Oct 24;381(17):1644–1652. PMID: PMC6961983
9. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. *J Biol Chem*. 2004 Apr 23;279(17):17181–17189. PMID: 14960586
10. Lima WF, Rose JB, Nichols JG, Wu H, Migawa MT, Wyrzykiewicz TK, Siwkowski AM, Crooke ST. Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. *Mol Pharmacol*. 2007 Jan;71(1):83–91. PMID: 17028158
11. Lima WF, Murray HM, Damle SS, Hart CE, Hung G, De Hoyos CL, Liang XH, Crooke ST.

- Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function. *Nucleic Acids Res.* 2016 20;44(11):5299–5312. PMID: PMC4914116
12. Jafar-Nejad P, Powers B, Soriano A, Zhao H, Norris DA, Matson J, DeBrosse-Serra B, Watson J, Narayanan P, Chun SJ, Mazur C, Kordasiewicz H, Swayze EE, Rigo F. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. *Nucleic Acids Res.* 2021 Jan 25;49(2):657–673. PMID: PMC7826274
 13. Rigo F, Chun SJ, Norris DA, Hung G, Lee S, Matson J, Fey RA, Gaus H, Hua Y, Grundy JS, Krainer AR, Henry SP, Bennett CF. Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. *J Pharmacol Exp Ther.* 2014 Jul;350(1):46–55. PMID: PMC4056267
 14. Hagemann TL, Powers B, Lin NH, Mohamed AF, Dague KL, Hannah SC, Bachmann G, Mazur C, Rigo F, Olsen AL, Feany MB, Perng MD, Berman RF, Messing A. Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment. *Sci Transl Med.* 2021 Nov 17;13(620):eabg4711. PMID: PMC8730534
 15. Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. *Nature.* 2017 Apr 20;544(7650):362–366. PMID: 28405024
 16. McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, Luo Y, Zhang M, Thankamony S, Salzman DW, Cudkowicz M, Graham DL, Bennett CF, Kordasiewicz HB, Swayze EE, Miller TM, Comfort N, Wang B, Amacker J. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. *J Clin Invest.* 2018 01;128(8):3558–3567. PMID: PMC6063493
 17. Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. LRRK2 Antisense Oligonucleotides Ameliorate α -Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model. *Mol Ther Nucleic Acids.* 2017 Sep 15;8:508–519. PMID: PMC5573879
 18. Schoch KM, Ezerskiy LA, Morhaus MM, Bannon RN, Sauerbeck AD, Shabsovich M, Jafar-Nejad P, Rigo F, Miller TM. Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice. *Proc Natl Acad Sci U S A.* 2021 Jul 6;118(27):e2100356118. PMID: PMC8271763
 19. Friedrich J, Kordasiewicz HB, O'Callaghan B, Handler HP, Wagener C, Duvick L, Swayze EE, Rainwater O, Hofstra B, Benneyworth M, Nichols-Meade T, Yang P, Chen Z, Ortiz JP, Clark HB, Öz G, Larson S, Zoghbi HY, Henzler C, Orr HT. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. *JCI Insight.* 2018 02;3(21). PMID: PMC6238731
 20. Cole TA, Zhao H, Collier TJ, Sandoval I, Sortwell CE, Steece-Collier K, Daley BF, Booms A, Lipton J, Welch M, Berman M, Jandreski L, Graham D, Weihofen A, Celano S, Schulz E, Cole-Strauss A, Luna E, Quach D, Mohan A, Bennett CF, Swayze EE, Kordasiewicz HB, Luk KC, Paumier KL. α -Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. *JCI Insight.* 2021 Mar 8;6(5):e135633, 135633. PMID: PMC8021121
 21. Vallabh SM, Minikel EV, Schreiber SL, Lander ES. Towards a treatment for genetic prion disease: trials and biomarkers. *Lancet Neurol.* 2020 Apr;19(4):361–368. PMID: 32199098
 22. Minikel EV, Zhao HT, Le J, O'Moore J, Pitstick R, Graffam S, Carlson GA, Kavanaugh MP, Kriz J, Kim JB, Ma J, Wille H, Aiken J, McKenzie D, Doh-Ura K, Beck M, O'Keefe R,

- Stathopoulos J, Caron T, Schreiber SL, Carroll JB, Kordasiewicz HB, Cabin DE, Vallabh SM. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. *Nucleic Acids Res.* 2020 Aug 10; PMID: 32776089
23. Vanderburg C, Martin C, Kozareva V, Nadaf N, Patel N, Macosko E. Fresh Frozen Mouse Brain Preparation (for Single Nuclei Sequencing). 2020 Feb 14 [cited 2023 Jan 12]; Available from: <https://www.protocols.io/view/fresh-frozen-mouse-brain-preparation-for-single-nu-bcbrism6>
 24. Biancalani T, Scalia G, Buffoni L, Avasthi R, Lu Z, Sanger A, Tokcan N, Vanderburg CR, Segerstolpe Å, Zhang M, Avraham-Davidi I, Vickovic S, Nitzan M, Ma S, Subramanian A, Lipinski M, Buenrostro J, Brown NB, Fanelli D, Zhuang X, Macosko EZ, Regev A. Deep learning and alignment of spatially resolved single-cell transcriptomes with Tangram. *Nat Methods.* 2021 Nov;18(11):1352–1362. PMID: PMC8566243
 25. Vallabh SM, Nobuhara CK, Llorens F, Zerr I, Parchi P, Capellari S, Kuhn E, Klickstein J, Safar JG, Nery FC, Swoboda KJ, Geschwind MD, Zetterberg H, Arnold SE, Minikel EV, Schreiber SL. Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. *Proc Natl Acad Sci U S A.* 2019 Apr 1;201901947. PMID: 30936307
 26. Kozareva V, Martin C, Osorno T, Rudolph S, Guo C, Vanderburg C, Nadaf N, Regev A, Regehr WG, Macosko E. A transcriptomic atlas of mouse cerebellar cortex comprehensively defines cell types. *Nature.* 2021 Oct;598(7879):214–219. PMID: PMC8494635
 27. Martin C, Abdul A, Vanderburg C, Nadaf N, Feirrer A, Macosko E. Frozen Tissue Nuclei Extraction (for 10xV3 snSEQ). 2020 Feb 19 [cited 2023 Jan 12]; Available from: <https://www.protocols.io/view/frozen-tissue-nuclei-extraction-for-10xv3-snseq-bck6iuz>
 28. Kamath T, Abdulraouf A, Burris SJ, Langlieb J, Gazestani V, Nadaf NM, Balderrama K, Vanderburg C, Macosko EZ. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease. *Nat Neurosci.* 2022 May;25(5):588–595. PMID: PMC9076534
 29. 10X Genomics. USER GUIDE: Chromium Next GEM Single Cell 3' Reagent Kits v3.1 (Dual Index). CG000315 Rev E. [Internet]. 2022 [cited 2023 Jan 24]. Available from: https://web.archive.org/web/20230118215722/https://cdn.10xgenomics.com/image/upload/v1668017706/support-documents/CG000315_ChromiumNextGEMSingleCell3-_GeneExpression_v3.1_DualIndex__RevE.pdf
 30. Li B, Gould J, Yang Y, Sarkizova S, Tabaka M, Ashenberg O, Rosen Y, Slyper M, Kowalczyk MS, Villani AC, Tickle T, Hacohen N, Rozenblatt-Rosen O, Regev A. Cumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus RNA-seq. *Nat Methods.* 2020 Aug;17(8):793–798. PMID: PMC7437817
 31. Zheng GXY, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, Ziraldo SB, Wheeler TD, McDermott GP, Zhu J, Gregory MT, Shuga J, Montesclaros L, Underwood JG, Masquelier DA, Nishimura SY, Schnall-Levin M, Wyatt PW, Hindson CM, Bharadwaj R, Wong A, Ness KD, Beppu LW, Deeg HJ, McFarland C, Loeb KR, Valente WJ, Ericson NG, Stevens EA, Radich JP, Mikkelsen TS, Hindson BJ, Bielas JH. Massively parallel digital transcriptional profiling of single cells. *Nat Commun.* 2017 Jan 16;8:14049. PMID: PMC5241818
 32. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction [Internet]. arXiv; 2018. Available from: <https://arxiv.org/abs/1802.03426>
 33. Zeisel A, Muñoz-Manchado AB, Codeluppi S, Lönnerberg P, La Manno G, Juréus A, Marques S, Munguba H, He L, Betsholtz C, Rolny C, Castelo-Branco G, Hjerling-Leffler J, Linnarsson S. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science.* 2015 Mar 6;347(6226):1138–1142. PMID: 25700174
 34. Li Y, Lopez-Huerta VG, Adiconis X, Levandowski K, Choi S, Simmons SK, Arias-Garcia

- MA, Guo B, Yao AY, Blosser TR, Wimmer RD, Aida T, Atamian A, Naik T, Sun X, Bi D, Malhotra D, Hession CC, Shema R, Gomes M, Li T, Hwang E, Krol A, Kowalczyk M, Peça J, Pan G, Halassa MM, Levin JZ, Fu Z, Feng G. Distinct subnetworks of the thalamic reticular nucleus. *Nature*. 2020 Jul;583(7818):819–824. PMID: PMC7394718
35. Han L, Wei X, Liu C, Volpe G, Zhuang Z, Zou X, Wang Z, Pan T, Yuan Y, Zhang X, Fan P, Guo P, Lai Y, Lei Y, Liu X, Yu F, Shangguan S, Lai G, Deng Q, Liu Y, Wu L, Shi Q, Yu H, Huang Y, Cheng M, Xu J, Liu Y, Wang M, Wang C, Zhang Y, Xie D, Yang Y, Yu Y, Zheng H, Wei Y, Huang F, Lei J, Huang W, Zhu Z, Lu H, Wang B, Wei X, Chen F, Yang T, Du W, Chen J, Xu S, An J, Ward C, Wang Z, Pei Z, Wong CW, Liu X, Zhang H, Liu M, Qin B, Schambach A, Isern J, Feng L, Liu Y, Guo X, Liu Z, Sun Q, Maxwell PH, Barker N, Muñoz-Cánoves P, Gu Y, Mulder J, Uhlen M, Tan T, Liu S, Yang H, Wang J, Hou Y, Xu X, Esteban MA, Liu L. Cell transcriptomic atlas of the non-human primate *Macaca fascicularis*. *Nature*. 2022 Apr;604(7907):723–731. PMID: 35418686
36. Vanlandewijck M, He L, Mäe MA, Andrae J, Ando K, Del Gaudio F, Nahar K, Lebouvier T, Laviña B, Gouveia L, Sun Y, Raschperger E, Räsänen M, Zarb Y, Mochizuki N, Keller A, Lendahl U, Betsholtz C. A molecular atlas of cell types and zonation in the brain vasculature. *Nature*. 2018 Feb 22;554(7693):475–480. PMID: 29443965
37. Mickelsen LE, Flynn WF, Springer K, Wilson L, Beltrami EJ, Bolisetty M, Robson P, Jackson AC. Cellular taxonomy and spatial organization of the murine ventral posterior hypothalamus. *Elife*. 2020 Oct 29;9:e58901. PMID: PMC7595735
38. Yao Z, van Velthoven CTJ, Nguyen TN, Goldy J, Sedeno-Cortes AE, Baftizadeh F, Bertagnolli D, Casper T, Chiang M, Crichton K, Ding SL, Fong O, Garren E, Glandon A, Gouwens NW, Gray J, Graybuck LT, Hawrylycz MJ, Hirschstein D, Kroll M, Lathia K, Lee C, Levi B, McMillen D, Mok S, Pham T, Ren Q, Rimorin C, Shapovalova N, Sulc J, Sunkin SM, Tieu M, Torkelson A, Tung H, Ward K, Dee N, Smith KA, Tasic B, Zeng H. A taxonomy of transcriptomic cell types across the isocortex and hippocampal formation. *Cell*. 2021 Jun 10;184(12):3222–3241.e26. PMID: PMC8195859
39. Chen A, Sun Y, Lei Y, Li C, Liao S, Liang Z, Lin F, Yuan N, Li M, Wang K, Yang M, Zhang S, Zhuang Z, Meng J, Song Q, Zhang Y, Xu Y, Cui L, Han L, Yang H, Sun X, Fei T, Chen B, Li W, Huangfu B, Ma K, Li Z, Lin Y, Liu Z, Wang H, Zhong Y, Zhang H, Yu Q, Wang Y, Zhu Z, Liu X, Peng J, Liu C, Chen W, An Y, Xia S, Lu Y, Wang M, Song X, Liu S, Wang Z, Gong C, Huang X, Yuan Y, Zhao Y, Luo Z, Tan X, Liu J, Zheng M, Li S, Huang Y, Hong Y, Huang Z, Li M, Zhang R, Jin M, Li Y, Zhang H, Sun S, Bai Y, Cheng M, Hu G, Liu S, Wang B, Xiang B, Li S, Li H, Chen M, Wang S, Zhang Q, Liu W, Liu X, Zhao Q, Lisby M, Wang J, Fang J, Lu Z, Lin Y, Xie Q, He J, Xu H, Huang W, Wei W, Yang H, Sun Y, Poo M, Wang J, Li Y, Shen Z, Liu L, Liu Z, Xu X, Li C. Global Spatial Transcriptome of Macaque Brain at Single-Cell Resolution. *bioRxiv*. 2022 Jan 1;2022.03.23.485448.
40. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, Hoffman P, Stoeckius M, Papalexi E, Mimitou EP, Jain J, Srivastava A, Stuart T, Fleming LM, Yeung B, Rogers AJ, McElrath JM, Blish CA, Gottardo R, Smibert P, Satija R. Integrated analysis of multimodal single-cell data. *Cell*. 2021 Jun 24;184(13):3573–3587.e29. PMID: PMC8238499
41. Raymond GJ, Zhao HT, Race B, Raymond LD, Williams K, Swayze EE, Graffam S, Le J, Caron T, Stathopoulos J, O’Keefe R, Lubke LL, Reidenbach AG, Kraus A, Schreiber SL, Mazur C, Cabin DE, Carroll JB, Minikel EV, Kordasiewicz H, Caughey B, Vallabh SM. Antisense oligonucleotides extend survival of prion-infected mice. *JCI Insight*. 2019 30;5. PMID: 31361599
42. Freier SM, Bui HH, Zhao H. Compounds and methods for reducing prion expression [Internet]. WO2020106996A1, 2020 [cited 2021 Jan 22]. Available from: <https://patents.google.com/patent/WO2020106996A1/en>
43. Mortberg MA, Zhao HT, Reidenbach AG, Gentile JE, Kuhn E, O’Moore J, Dooley PM,

- Connors TR, Mazur C, Allen SW, Trombetta BA, McManus A, Moore MR, Liu J, Cabin DE, Kordasiewicz HB, Mathews J, Arnold SE, Vallabh SM, Minikel EV. Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS. *JCI Insight*. 2022 Mar 22;7(6):e156532. PMID: PMC8986079
44. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z, Zhang MQ, Sedel F, Jourdain L, Couplier F, Triller A, Spector DL, Bessis A. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. *EMBO J*. 2010 Sep 15;29(18):3082–3093. PMID: PMC2944070
 45. Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. Pharmacology of Antisense Drugs. *Annu Rev Pharmacol Toxicol*. 2017 Jan 6;57:81–105. PMID: 27732800
 46. Anderson BA, Freestone GC, Low A, De-Hoyos CL, Iii WJD, Østergaard ME, Migawa MT, Fazio M, Wan WB, Berdeja A, Scandalis E, Burel SA, Vickers TA, Crooke ST, Swayze EE, Liang X, Seth PP. Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. *Nucleic Acids Res*. 2021 Sep 20;49(16):9026–9041. PMID: PMC8450106
 47. Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA, Prakash TP, Migawa MT, Bhat B, Swayze EE. Synthesis and biophysical evaluation of 2',4'-constrained 2'-O-methoxyethyl and 2',4'-constrained 2'-O-ethyl nucleic acid analogues. *J Org Chem*. 2010 Mar 5;75(5):1569–1581. PMID: 20136157
 48. Brautigam H, Steele JW, Westaway D, Fraser PE, St George-Hyslop PH, Gandy S, Hof PR, Dickstein DL. The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer's disease. *Mol Neurodegener*. 2012 Nov 22;7:58. PMID: PMC3551697
 49. Herculano-Houzel S, Messeder DJ, Fonseca-Azevedo K, Pantoja NA. When larger brains do not have more neurons: increased numbers of cells are compensated by decreased average cell size across mouse individuals. *Front Neuroanat*. 2015;9:64. PMID: PMC4450177
 50. Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, Sánchez-Guardado L, Lois C, Mazmanian SK, Deverman BE, Gradinaru V. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat Neurosci*. 2017 Aug;20(8):1172–1179. PMID: PMC5529245
 51. Crooke ST, Vickers TA, Liang XH. Phosphorothioate modified oligonucleotide-protein interactions. *Nucleic Acids Res*. 2020 Jun 4;48(10):5235–5253. PMID: PMC7261153
 52. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*. 2020 Sep 11;369(6509):1318–1330. PMID: PMC7737656
 53. Mortberg MA, Vallabh SM, Minikel EV. Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. *Sci Rep*. 2022 Oct 21;12(1):17708. PMID: PMC9587287
 54. Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, Rios-Romenets S, Giraldo M, Acosta N, Tobon C, Ramos C, Espinosa A, Cho W, Ward M, Clayton D, Friesenhahn M, Mackey H, Honigberg L, Sanabria Bohorquez S, Chen K, Walsh T, Langlois C, Reiman EM, Alzheimer's Prevention Initiative. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. *Alzheimers Dement (N Y)*. 2018;4:150–160. PMID: PMC6021543
 55. Minikel EV, Vallabh SM, Orseth MC, Brandel JP, Haïk S, Laplanche JL, Zerr I, Parchi P, Capellari S, Safar J, Kenny J, Fong JC, Takada LT, Ponto C, Hermann P, Knipper T, Stehmann C, Kitamoto T, Ae R, Hamaguchi T, Sanjo N, Tsukamoto T, Mizusawa H, Collins SJ, Chiesa R, Roiter I, de Pedro-Cuesta J, Calero M, Geschwind MD, Yamada M,

- Nakamura Y, Mead S. Age at onset in genetic prion disease and the design of preventive clinical trials. *Neurology*. 2019 Jun 6; PMID: 31171647
56. Prusiner SB. Prions. *Proc Natl Acad Sci USA*. 1998 Nov 10;95(23):13363–13383. PMID: PMC33918
 57. Mortberg MA, Minikel EV, Vallabh SM. Analysis of non-human primate models for evaluating prion disease therapeutic efficacy. *PLoS Pathog*. 2022 Aug 22;18(8):e1010728. PMID: 35994510
 58. Krejciova Z, Alibhai J, Zhao C, Krencik R, Rzechorzek NM, Ullian EM, Manson J, Ironside JW, Head MW, Chandran S. Human stem cell-derived astrocytes replicate human prions in a PRNP genotype-dependent manner. *J Exp Med*. 2017 Dec 4;214(12):3481–3495. PMID: PMC5716027
 59. Aguzzi A, Liu Y. A role for astroglia in prion diseases. *J Exp Med*. 2017 Dec 4;214(12):3477–3479. PMID: PMC5716049
 60. Lakkaraju AKK, Sorce S, Senatore A, Nuvolone M, Guo J, Schwarz P, Moos R, Pelczar P, Aguzzi A. Glial activation in prion diseases is selectively triggered by neuronal PrPSc. *Brain Pathol*. 2022 Feb 17;e13056. PMID: 35178783
 61. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A. Normal host prion protein necessary for scrapie-induced neurotoxicity. *Nature*. 1996 Jan 25;379(6563):339–343. PMID: 8552188
 62. Mallucci G, Dickinson A, Linehan J, Klöhn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. *Science*. 2003 Oct 31;302(5646):871–874. PMID: 14593181
 63. Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, Baxter D, Pitstick R, Young R, Spicer D, Price ND, Hohmann JG, Dearmond SJ, Carlson GA, Hood LE. A systems approach to prion disease. *Mol Syst Biol*. 2009;5:252. PMID: PMC2671916
 64. Sorce S, Nuvolone M, Russo G, Chincisan A, Heinzer D, Avar M, Pfammatter M, Schwarz P, Delic M, Hornemann S, Sanoudou D, Scheckel C, Aguzzi A. Genome-wide transcriptomics identifies an early preclinical signature of prion infection. *bioRxiv*. 2020 Jan 11;2020.01.10.901637.
 65. Slota JA, Sajesh BV, Frost KF, Medina SJ, Booth SA. Dysregulation of neuroprotective astrocytes, a spectrum of microglial activation states, and altered hippocampal neurogenesis are revealed by single-cell RNA sequencing in prion disease. *Acta Neuropathol Commun*. 2022 Nov 9;10(1):161. PMID: PMC9647949
 66. Dimitriadis A, Zhang F, Murphy T, Trainer T, Jaunmuktane Z, Schmidt C, Nazari T, Linehan J, Brandner S, Collinge J, Mead S, Viré E. Single-nuclei transcriptomics of mammalian prion diseases identifies dynamic gene signatures shared between species. *bioRxiv*. 2022 Jan 1;2022.09.13.507650.
 67. Nazor Friberg K, Hung G, Wancewicz E, Giles K, Black C, Freier S, Bennett F, Dearmond SJ, Freyman Y, Lessard P, Ghaemmaghami S, Prusiner SB. Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice. *Mol Ther Nucleic Acids*. 2012;1:e9. PMID: PMC3381600

SUPPLEMENTARY MATERIAL

Tables S1 - S17 are available in the attached Excel file or as tab-separated text files at <https://github.com/ericminikel/scaso>




Figure S1. Weeks post-dose and treatment group in UMAP space. UMAP plots from Figure 1 colored by treatment group (left) or weeks post-dose (right). Twinning of some cell types, particularly in mouse cortex, is due to a batch effect between 3-week versus 2- and 12-week post-dose animals; clusters are generally well-balanced between active and inactive treatment groups.